# An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.

> **NCT06891287** · PHASE1 · RECRUITING · sponsor: **RANI Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- Obesity

## Interventions

- **COMBINATION_PRODUCT:** RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity
- **DRUG:** PG-102
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06891287
- **Lead sponsor:** RANI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891287, "An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06891287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*